There was also a 96% reduction in risk compared with background HIV incidence of 2.37 per 100 person-years among individuals ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly ...